Please select the option that best describes you:
Are you treating with the superoxide dismutase mimetic Avasopasem (GC4419) for patients receiving chemoradiation for head & neck cancers?
After the randomized Phase IIb showed decreased mucositis, are you incorporating this agent? Please share your regimen and any tips.
Answer from: Radiation Oncologist at Academic Institution
This drug is not yet FDA-approved. It is currently under review by the FDA. I plan to use it after it is approved.
Sign in or Register to read more